-
1 Comment
Forward Pharma A/S is currently in a long term uptrend where the price is trading 11.8% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Forward Pharma A/S gets an overall score of 2/5.
| Industry | Biotechnology & Medical Research |
|---|---|
| Sector | Healthcare |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| ISIN | US34986J2042 |
| Target Price | 37 |
|---|---|
| PE Ratio | None |
| Market Cap | 14M |
| Beta | 1.38 |
| Dividend Yield | 0.0% |
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for FWP using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
